

Doramectin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5191215-00017 Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Doramectin Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Acute toxicity (Oral) : Category 5

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Central nervous system, Liver, Kidney)
repeated exposure (Oral)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

Hazard pictograms



Signal word

: Danger

Hazard statements

: H303 May be harmful if swallowed.
H360D May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system, Liver, Kidney) through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

: **Prevention:**

P203 Obtain, read and follow all safety instructions before use.
P260 Do not breathe mist or vapours.
P264 Wash hands thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P317 IF SWALLOWED: Get medical help.
P308 + P316 IF exposed or concerned: Get emergency medical help immediately.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Doramectin	117704-25-3	>= 1 - < 2.5

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

	When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: May be harmful if swallowed. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types: Strong oxidizing agents

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Doramectin	117704-25-3	TWA	35 µg/m ³ (OEB 3)	Internal
		Further information: Skin		

Engineering measures

- : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	oily
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	-7 °C
Initial boiling point and boiling range	:	270 °C
Flash point	:	215.7 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	0.89 - 91
Density	:	No data available
Solubility(ies)		
Water solubility	:	practically insoluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	31.7 - 32.1 m2/s (25 °C)
Explosive properties	:	Not explosive

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation
	:	Skin contact
	:	Ingestion
	:	Eye contact

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 5,000 mg/kg
	:	Method: Calculation method

Components:

Doramectin:

Acute oral toxicity	:	LD50 (Rat): 500 mg/kg Target Organs: Central nervous system
	:	LD50 (Mouse): > 2,000 mg/kg Target Organs: Central nervous system
	:	LD50 (Rat): 50 mg/kg Target Organs: Central nervous system
	:	LD50 (Mouse): 75 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 300 mg/kg Application Route: Intraperitoneal Target Organs: Central nervous system

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Doramectin:

Genotoxicity in vitro	: Test Type: Ames test Result: negative
	Test Type: Mouse Lymphoma Result: negative
	Test Type: unscheduled DNA synthesis assay Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Doramectin:

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

Reproductive toxicity

May damage the unborn child.

Components:

Doramectin:

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: NOAEL: 0.3 mg/kg body weight
-------------------------------	---

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019



Symptoms: Reduced body weight

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

Embryo-foetal toxicity: NOAEL: 3 mg/kg body weight

Symptoms: Embryolethal effects

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.75 mg/kg body weight

Symptoms: Maternal effects, Embryotoxic effects.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Doramectin:

Exposure routes : Oral
Target Organs : Central nervous system
Assessment : Shown to produce significant health effects in animals at concentrations of 300 mg/kg bw or less.

STOT - repeated exposure

May cause damage to organs (Central nervous system, Liver, Kidney) through prolonged or repeated exposure if swallowed.

Components:

Doramectin:

Exposure routes : Oral
Target Organs : Central nervous system, Liver, Kidney
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

Doramectin:

Species : Rat
LOAEL : 30 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Central nervous system

Species : Rat
NOAEL : 2 mg/kg

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5191215-00017 Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Central nervous system, Liver, Kidney
Species	:	Dog
NOAEL	:	2 mg/kg
Application Route	:	Oral
Exposure time	:	36 d
Target Organs	:	Eye
Symptoms	:	Dilatation of the pupil
Species	:	Dog
NOAEL	:	0.1 mg/kg
Application Route	:	Oral
Exposure time	:	92 d
Target Organs	:	Central nervous system, Eye
Symptoms	:	Dilatation of the pupil

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Doramectin:

Skin contact	:	Target Organs: Gastro-intestinal system Symptoms: Nausea, Diarrhoea Target Organs: Central nervous system Symptoms: Dizziness, Headache Target Organs: Eye Symptoms: Irritation Target Organs: Skin Symptoms: Irritation Target Organs: Respiratory system Symptoms: Breathing difficulties
Ingestion	:	Target Organs: Gastro-intestinal system Symptoms: Nausea, Abdominal pain, Diarrhoea Target Organs: Central nervous system Symptoms: Dizziness

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Doramectin:

Toxicity to fish	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): 11 µg/l Exposure time: 96 h Method: OECD Test Guideline 203
		LC50 (Oncorhynchus mykiss (rainbow trout)): 5.1 µg/l Exposure time: 96 h

Doramectin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5191215-00017 Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.1 µg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

M-Factor (Chronic aquatic toxicity) : 10,000

Ecotoxicology Assessment

Acute aquatic toxicity : Very toxic to aquatic life.

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Doramectin:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 71
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.5
pH: 7

Mobility in soil

Components:

Doramectin:

Distribution among environmental compartments : log Koc: 4.94

Other adverse effects

Components:

Doramectin:

Results of PBT and vPvB assessment : Substance is not very persistent and very bioaccumulative (vPvB).

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version 7.0 Revision Date: 14.04.2025 SDS Number: 5191215-00017 Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Doramectin)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Doramectin)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Doramectin)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version 7.0	Revision Date: 14.04.2025	SDS Number: 5191215-00017	Date of last issue: 24.02.2025 Date of first issue: 22.10.2019
----------------	------------------------------	------------------------------	---

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

SAFETY DATA SHEET

according to the Globally Harmonized System



Doramectin Formulation

Version
7.0

Revision Date:
14.04.2025

SDS Number:
5191215-00017

Date of last issue: 24.02.2025
Date of first issue: 22.10.2019

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN